Shrinidhi Nathany: Why the Theriome Matters More Than We Think
Shrinidhi Nathany, Consultant Molecular Hematology and Oncology at Fortis Memorial, posted on LinkedIn:
“Sunday learning with the boss Dr. Rahul Bhargava
After a break back with a bang.. with more new concepts
As i started a thread on theriome, i will continue that today
Why the Theriome Matters More Than We Think
We often ask why patients with the same diagnosis and similar mutations have very different outcomes.
The answer often lies in the theriome.
The theriome influences how aggressively a tumour behaves, how it escapes the immune system and how it responds or fails to respond to therapy. In hematologic malignancies, the bone marrow and lymphoid niche can actively protect malignant cells from chemotherapy and targeted drugs.
This is why genomics alone is sometimes not enough. To truly understand cancer behaviour, we must also understand the ecosystem in which the cancer lives.”
Stay informed with Hemostasis Today.
-
May 9, 2026, 05:03Marlene S: New WFH Initiative on Equity in Bleeding Disorder Care
-
May 9, 2026, 04:49Why Early Recognition in Bleeding Disorders Saves Lives – EHC
-
May 8, 2026, 19:37Mostafa Faisal Mohammed Saleh: Exploring the Role of AI and Learning in Monitoring Iron Overload in Beta-Thalassemia
-
May 8, 2026, 19:27Spelile Mutupira: Hemostasis – How the Body Stops Bleeding Naturally
-
May 8, 2026, 19:15Not All TF Activity Assays Measure Tissue Factor – RPTH Journal
-
May 8, 2026, 18:48Carlos Penalillo Pimentel: Detection of Rare Blood Donor Phenotypes During Investigation of Serologic Discrepancies
-
May 8, 2026, 18:23How SCD Affects Daily Life in sub-Saharan Africa? – American Society of Hematology
-
May 8, 2026, 18:03Risk of Thrombosis After Stopping Anticoagulation in APS With aPL Negativization -JTH
-
May 8, 2026, 17:35Gurpreet Kaur Sagoo: A Rare Bone Marrow Failure Syndrome That Challenges Early Diagnosis